Literature DB >> 19134029

Articular status of haemophilia patients with inhibitors.

M Morfini1.   

Abstract

The incidence of haemarthrosis is similar in young haemophilia patients with or without inhibitors, but whether this is due to the effect of modern therapy is unknown. In comparison with younger patients with haemophilia, older haemophilia patients have a lower incidence of haemarthrosis because of very severe arthropathy (crippled joints). It is not known whether this could be due to the lack of therapy in previous years. In addition, the burden of orthopaedic complications and the impact on quality of life are more severe in patients with haemophilia who have developed an inhibitor compared with those without inhibitors. This article describes the results of the European Study on Orthopaedic Status of Haemophilia Patients with inhibitors (ESOS) which set out to determine how the inhibitor status of haemophilia patients may influence their quality of life and degree of arthropathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19134029     DOI: 10.1111/j.1365-2516.2008.01885.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  4 in total

1.  Emicizumab should be prescribed independent of immune tolerance induction.

Authors:  Sandra Le Quellec; Claude Negrier
Journal:  Blood Adv       Date:  2018-10-23

2.  Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors.

Authors:  Hussain I Saba; Duc Quang Tran
Journal:  J Blood Med       Date:  2011-05-18

3.  Manual therapy in the treatment of patients with hemophilia B and inhibitor.

Authors:  Rubén Cuesta-Barriuso; Roberto O Trelles-Martínez
Journal:  BMC Musculoskelet Disord       Date:  2018-01-22       Impact factor: 2.362

Review 4.  Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.

Authors:  Georg Gelbenegger; Christian Schoergenhofer; Paul Knoebl; Bernd Jilma
Journal:  Thromb Haemost       Date:  2020-07-27       Impact factor: 5.249

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.